130 related articles for article (PubMed ID: 34738358)
21. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
22. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
23. Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma.
Tang XX; Shimada H; Ikegaki N
Genes Immun; 2022 Jun; 23(3-4):129-140. PubMed ID: 35525858
[TBL] [Abstract][Full Text] [Related]
24. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
25. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Harshman LC; Choueiri TK; Drake C; Stephen Hodi F
Cancer J; 2014; 20(4):272-80. PubMed ID: 25098288
[TBL] [Abstract][Full Text] [Related]
26. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
Liu M; Sun Q; Wei F; Ren X
Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
[TBL] [Abstract][Full Text] [Related]
28. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
29. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
30. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
32. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
He Y; Liu S; Mattei J; Bunn PA; Zhou C; Chan D
Drug Des Devel Ther; 2018; 12():981-986. PubMed ID: 29731605
[TBL] [Abstract][Full Text] [Related]
33. Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma.
Zuo S; Sho M; Sawai T; Kanehiro H; Maeda K; Yoshida M; Tsukada R; Nomura M; Okuyama H
Pediatr Surg Int; 2020 Feb; 36(2):137-143. PubMed ID: 31925505
[TBL] [Abstract][Full Text] [Related]
34. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
35. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
36. Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Toews K; Grunewald L; Schwiebert S; Klaus A; Winkler A; Ali S; Zirngibl F; Astrahantseff K; Wagner DL; Henssen AG; Deubzer HE; Schulte JH; Ochsenreither S; Eggert A; Künkele A
Mol Carcinog; 2020 Jul; 59(7):724-735. PubMed ID: 32333465
[TBL] [Abstract][Full Text] [Related]
37. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Lee KS; Yun S; Lee K; Moon S; Choe G
Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
[TBL] [Abstract][Full Text] [Related]
39. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
